Genmab: GEN3014's Demise And Implications For The HexaBody Platform
Genmab wisely chose not to pursue GEN3014 further, focusing instead on its existing pipeline projects. Click here to read an ...
Fierce Biotech5d
J&J opts out of licensing Genmab's Darzalex challenger after look at phase 1/2 data
Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter ...
Genmab sinks as J&J opts not to develop Darzalex successor; stock upgraded
Genmab (CSE:GMAB) (NASDAQ:GMAB) announced on Monday, March 10, that Johnson&Johnson (NYSE:JNJ) has chosen not to proceed with the development of GEN3014 (HexaBody-CD38), a next-gen version of their ...
pharmaphorum5d
J&J abandons work with Genmab on Darzalex successor
A head-to-head trial of HexaBody-CD38 versus Darzalex Faspro revealed an overall response rate (ORR) of 55% and 52%, respectively, with Genmab pointing to "deeper responses" with the new drug and a ...
China’s biotech is redrawing the global pharma map; what India can learn
American biggies are joining hands with Chinese companies. AbbVie signed a deal with Simcere Zaiming for a multiple myeloma ...
Yahoo Finance5d
Genmab sinks as J&J opts not to develop Darzalex successor; stock upgraded
The company held an investor call to discuss the decision, during which it shared initial data from a head-to-head study comparing GEN3014 to Darzalex. While the results suggested potentially deeper ...
Investing5d
Genmab sinks as J&J opts not to develop Darzalex successor; stock upgraded
The company held an investor call to discuss the decision, during which it shared initial data from a head-to-head study comparing GEN3014 to Darzalex. While the results suggested potentially ...
Investing5d
Genmab sinks as J&J opts not to develop Darzalex successor; stock upgraded
Investing.com -- Genmab (CSE:GMAB) (NASDAQ:GMAB) announced on Monday, March 10, that Johnson & Johnson (NYSE:JNJ) has chosen not to proceed with the development of GEN3014 (HexaBody-CD38), a next-gen ...